Differences between the European and Eurasian Good Pharmacovigilance Practices
Good pharmacovigilance practices (GVP) of the Eurasian Economic Union (EAEU) were prepared based on the GVP of the European Medicines Agency that have been in force in the European Union (EU) since 2012. The EAEU GVP have been in force in the Russian Federation and the other EAEU member states since...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2021-07-01
|
| Series: | Безопасность и риск фармакотерапии |
| Subjects: | |
| Online Access: | https://www.risksafety.ru/jour/article/view/220 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849252347410120704 |
|---|---|
| author | A. V. Matveev A. E. Krasheninnikov E. A. Matveeva B. K. Romanov |
| author_facet | A. V. Matveev A. E. Krasheninnikov E. A. Matveeva B. K. Romanov |
| author_sort | A. V. Matveev |
| collection | DOAJ |
| description | Good pharmacovigilance practices (GVP) of the Eurasian Economic Union (EAEU) were prepared based on the GVP of the European Medicines Agency that have been in force in the European Union (EU) since 2012. The EAEU GVP have been in force in the Russian Federation and the other EAEU member states since 2016. It is important to identify potential differences between the current regulations in order to harmonise requirements for the pharmacovigilance systems in the EU and EAEU. The aim of the study was to analyse and compare GVP requirements in the EU and EAEU. The analysis helped to identify differences in the structure and contents of GVP sections, the definitions of terms (EU GVP definitions are more detailed and supported by examples, subsections, and references to other documents). Moreover, supplements and annexes to the EU GVP contain figures, templates, examples, algorithms, and tables, which are missing in the EAEU GVP. Expert analysis of these differences as applied to assessment of the pharmacovigilance systems’ effectiveness, and practical activities of marketing authorisation holders, medicine developers, and regulatory authorities, demonstrated that the two GVPs are sufficiently harmonised and have very few differences. However, the number of differences between the documents increases, as changes are made to the EU GVP. A more comprehensive harmonisation of the EAEU GVP with the current version of the EU GVP will make it possible to develop and use uniform pharmacovigilance documents in the EU and EAEU, and will facilitate the introduction of EAEU medicines into the global pharmaceutical market. |
| format | Article |
| id | doaj-art-6f22f46453bd4c47bcd4283b7964942a |
| institution | Kabale University |
| issn | 2312-7821 2619-1164 |
| language | Russian |
| publishDate | 2021-07-01 |
| publisher | Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Безопасность и риск фармакотерапии |
| spelling | doaj-art-6f22f46453bd4c47bcd4283b7964942a2025-08-20T03:56:40ZrusMinistry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Безопасность и риск фармакотерапии2312-78212619-11642021-07-0192758410.30895/2312-7821-2021-9-2-75-84187Differences between the European and Eurasian Good Pharmacovigilance PracticesA. V. Matveev0A. E. Krasheninnikov1E. A. Matveeva2B. K. Romanov3National Scientific Center of Pharmacovigilance; Russian Medical Academy of Continuing Professional EducationNational Scientific Center of Pharmacovigilance; N. I. Pirogov Russian National Research Medical UniversityNational Scientific Center of Pharmacovigilance; Medical Academy named after S. I. Georgievsky of V. I. Vernadsky Crimean Federal UniversityN. I. Pirogov Russian National Research Medical University; Scientific Centre for Expert Evaluation of Medicinal ProductsGood pharmacovigilance practices (GVP) of the Eurasian Economic Union (EAEU) were prepared based on the GVP of the European Medicines Agency that have been in force in the European Union (EU) since 2012. The EAEU GVP have been in force in the Russian Federation and the other EAEU member states since 2016. It is important to identify potential differences between the current regulations in order to harmonise requirements for the pharmacovigilance systems in the EU and EAEU. The aim of the study was to analyse and compare GVP requirements in the EU and EAEU. The analysis helped to identify differences in the structure and contents of GVP sections, the definitions of terms (EU GVP definitions are more detailed and supported by examples, subsections, and references to other documents). Moreover, supplements and annexes to the EU GVP contain figures, templates, examples, algorithms, and tables, which are missing in the EAEU GVP. Expert analysis of these differences as applied to assessment of the pharmacovigilance systems’ effectiveness, and practical activities of marketing authorisation holders, medicine developers, and regulatory authorities, demonstrated that the two GVPs are sufficiently harmonised and have very few differences. However, the number of differences between the documents increases, as changes are made to the EU GVP. A more comprehensive harmonisation of the EAEU GVP with the current version of the EU GVP will make it possible to develop and use uniform pharmacovigilance documents in the EU and EAEU, and will facilitate the introduction of EAEU medicines into the global pharmaceutical market.https://www.risksafety.ru/jour/article/view/220pharmacovigilancegood pharmacovigilance practicesgvpeurasian economic unioneuropean unioneuropean medicines agency |
| spellingShingle | A. V. Matveev A. E. Krasheninnikov E. A. Matveeva B. K. Romanov Differences between the European and Eurasian Good Pharmacovigilance Practices Безопасность и риск фармакотерапии pharmacovigilance good pharmacovigilance practices gvp eurasian economic union european union european medicines agency |
| title | Differences between the European and Eurasian Good Pharmacovigilance Practices |
| title_full | Differences between the European and Eurasian Good Pharmacovigilance Practices |
| title_fullStr | Differences between the European and Eurasian Good Pharmacovigilance Practices |
| title_full_unstemmed | Differences between the European and Eurasian Good Pharmacovigilance Practices |
| title_short | Differences between the European and Eurasian Good Pharmacovigilance Practices |
| title_sort | differences between the european and eurasian good pharmacovigilance practices |
| topic | pharmacovigilance good pharmacovigilance practices gvp eurasian economic union european union european medicines agency |
| url | https://www.risksafety.ru/jour/article/view/220 |
| work_keys_str_mv | AT avmatveev differencesbetweentheeuropeanandeurasiangoodpharmacovigilancepractices AT aekrasheninnikov differencesbetweentheeuropeanandeurasiangoodpharmacovigilancepractices AT eamatveeva differencesbetweentheeuropeanandeurasiangoodpharmacovigilancepractices AT bkromanov differencesbetweentheeuropeanandeurasiangoodpharmacovigilancepractices |